# Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma

> **NCT01876212** · PHASE2 · COMPLETED · sponsor: **Walter J. Storkus** · enrollment: 15 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **BIOLOGICAL:** DC vaccine
- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT01876212
- **Lead sponsor:** Walter J. Storkus
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-16
- **Primary completion:** 2018-07-11
- **Final completion:** 2019-07-31
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2019-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01876212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01876212, "Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01876212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*